Please login to the form below
Pulmonary Hypertension
This page shows the latest Pulmonary Hypertension news and features for those working in and with pharma, biotech and healthcare.
Janssen’s single tablet combination shows promise in phase 3 PAH study
Around 500 to 1, 000 cases of pulmonary arterial hypertension are diagnosed each year in the US. ... a large number of pills each day to treat their PAH and various comorbidities,” explained Kelly Chin, professor of internal medicine and director of
Latest news
-
EC approves UCB’s Fintepla to treat severe form of epilepsy
placebo. The most common treatment-emergent adverse events were decreased appetite, fatigue and fever, the company reported, and no cases of valvular heart disease or pulmonary arterial hypertension were observed.
-
Enzyvant and Altavant announce merger to accelerate rare disease therapies
The company is also currently evaluating an investigational product, rodatristat ethyl, which is designed to address a root cause of pulmonary arterial hypertension.
-
Merck’s sotatercept shows promise as pulmonary arterial hypertension add-on treatment in phase 3 trial
the treatment of pulmonary arterial hypertension (PAH). ... PAH is a rare, progressive and life-threatening blood vessel disorder characterised by the constriction of small pulmonary arteries and elevated blood pressure in the pulmonary circulation,
-
Merck’s $11.5bn acquisition of Acceleron delayed
Merck announced plans to acquire Acceleron at the end of September to boost its cardiovascular portfolio through lead candidate sotatercept – a potentially first-in-class therapy for pulmonary arterial hypertension in
-
Merck to acquire Acceleron in a deal worth around $11.5bn
Acceleron’s focus is on the research, development and commercialisation of treatments in pulmonary and haematologic diseases with drugs that engage the ‘TGF-beta superfamily’, involved in the body’s ability ... 2 PULSAR clinical trial in patients
More from news
Approximately 1 fully matching, plus 91 partially matching documents found.
Latest Intelligence
-
My journey advancing the science in pulmonary hypertension
I anticipate continuing our work for a long while yet! Neil Davie is Head of Late Development, Cardiovascular, Metabolism &Pulmonary Hypertension at the Janssen Pharmaceutical Companies of Johnson &Johnson. . ... Neil Davie is Head of Late Development,
-
Understanding the ‘real world’ starts and ends with the patient
For the past 20 years, true understanding of the patient experience has been the turnkey for R&D for therapies in pulmonary arterial hypertension (PAH) at Janssen Pulmonary Hypertension (following the ... Neil Davie is Global Therapeutic Area Head,
-
AI: the smart money is on the smart thinking
Bayer and Merck &Co provide a perfect example of this. They have developed an AI software system to support clinical decision-making of chronic thromboembolic pulmonary hypertension (CTEPH) – a rare form ... of pulmonary hypertension.
-
Will biosimilars ever catch on in the US?
First-to-market generics included medicines for opioid overdose, pulmonary arterial hypertension, breast cancer, seizures, depression and various infections.
-
Is it time we stopped talking about adherence?
The EarthWorks has employed this philosophy to develop award-winning patient support programmes in chronic conditions such as asthma and HIV, and rare, complex conditions such as pulmonary arterial hypertension.
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest appointments
-
New faces at Lucid, 90Ten and Page & Page
Downey has 15 years’ medical communications experience, with expertise in several therapy areas, including MS and pulmonary hypertension.
-
J&J's Jane Griffiths named global head of Actelion
At that point it will gain marketed products that include a trio of pulmonary artery hypertension (PAH) drugs - Tracleer (bosentan), Opsumit (macitentan) and Uptravi (selexipag).
-
Kite Pharma appoints Zelboraf scientist as CMO
Prior to joining Plexxikon, Dr Nolop was VP of clinical research at CoTherix, where he led the development and US approval for Ventavis (iloprost) to treat pulmonary arterial hypertension (PAH).
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Sharing patient stories for World Pulmonary Hypertension Day
For World Pulmonary Hypertension Day and we’re here to help raise awareness of pulmonary hypertension (PH) - a frequently under and misdiagnosed condition.
-
Lucid kick-starts 2019 with spellbinding new additions to its writing and account teams
Elaine Downey joins Vivid as a Senior Account Manager; she has over 15 years’ medical communications experience, with expertise in several therapy areas, including MS and pulmonary hypertension.
-
COUCH Health
Sharing patient stories for World Pulmonary Hypertension Day. ... For World Pulmonary Hypertension Day and we’re here to help raise awareness of pulmonary hypertension (PH) - a frequently under and misdiagnosed condition.
More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Senior Medical Writer
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- PMGroup announces launch of new recruitment platform PharmaRole
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- BioNTech reveals plans to spend about €1bn more on research and development this year
- AstraZeneca’s mild combination asthma reliever approved in UK
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- MHRA to introduce new UK clinical trials framework
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
- Inizio appoints Stefanie Christmas as global head of DE&I
- The Considered appoints Bam Zahraie as chief experience officer
PMHub
COUCH Health
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
